Key facts
- Allay Therapeutics’s last known valuation is $126.0M (Jun 2025).
- It has raised $174.8M across 3 recorded rounds; the latest was Early Stage VC ($45.0M) in Jan 2025.
- Notable investors include New Enterprise Associates, Temasek Holdings, EDBI, SGInnovate, Vertex Growth — 19 tracked in total.
- Allay Therapeutics has filed 4 Form Ds with the SEC since 2021, most recently Feb 2025 ($45.0M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Allay Therapeutics
Funding rounds
3 roundsAbout Allay Therapeutics
Developer of sustained analgesic products designed to provide post-surgical pain management and recuperation for patients and physicians. The company's platform combines validated local analgesics and biopolymers in dissolvable candidates designed to deliver pain relief and address the drawbacks of opioids, enabling patients to get through the phase of recuperation in a simplified way.
- Sector
- Healthcare
- HQ
- San Jose, CA, United States
- Founded
- 2016
- Employees
- 50
- Website
- allaytx.com/
- Ownership
- Privately Held (backing)
Allay Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Allay Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Allay Therapeutics in its N-PORT filings yet. We sweep new filings monthly.